A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset Psychosis
NCT00216580 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2013-03-25
Summary
The purpose of the study is to assess the effectiveness and safety of long-acting injectable risperidone in the treatment of patients in the early stage of psychosis
Conditions
Interventions
- DRUG
-
Risperidone, long-acting injectable
Sponsors & Collaborators
-
Janssen Pharmaceutica N.V., Belgium
lead INDUSTRY
Principal Investigators
-
Janssen Pharmaceutica N.V. Clinical Trial · Janssen Pharmaceutica N.V.
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 16 Years
- Max Age
- 45 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-02-29
- Completion
- 2006-12-31
More Related Trials
-
A Pharmacokinetic and Safety Study of Risperidone Long Acting Injectable in Schizophrenic Patients
NCT00653406 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluation of the Efficacy and Safety of Risperidone Injections Given Once a Month to Adults With Schizophrenia or Schizoaffective Disorder
NCT00236353 ·Status: COMPLETED ·Phase: PHASE3
-
Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode
NCT00216671 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-acting Risperidone by Injection
NCT00236548 ·Status: COMPLETED ·Phase: PHASE3
-
A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis
NCT00246259 ·Status: COMPLETED ·Phase: PHASE4
-
Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia
NCT00330551 ·Status: COMPLETED ·Phase: PHASE4
-
An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia
NCT01894984 ·Status: TERMINATED
-
A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.
NCT00495118 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)
NCT00216632 ·Status: COMPLETED ·Phase: PHASE4
-
A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic Schizophrenia
NCT00249223 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia
NCT00246285 ·Status: COMPLETED ·Phase: PHASE3
-
A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode
NCT00378092 ·Status: COMPLETED ·Phase: PHASE4
-
Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis
NCT00369239 ·Status: COMPLETED ·Phase: PHASE4
-
Long-Acting Injectable Risperidone in the Treatment of Schizophrenia
NCT00132314 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres
NCT00216528 ·Status: COMPLETED ·Phase: PHASE4
-
An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia
NCT00269919 ·Status: COMPLETED ·Phase: PHASE4
-
An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders
NCT01855074 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder
NCT00297388 ·Status: COMPLETED ·Phase: PHASE3
-
Medical Chart Review of Patients on Long-term Treatment With Long-acting Injectable Risperidone
NCT00644852 ·Status: COMPLETED
-
A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
NCT00236457 ·Status: COMPLETED ·Phase: PHASE3
-
RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain Information on the Safety and Efficacy of Risperidone When Used in Routine Clinical Practice
NCT00458367 ·Status: COMPLETED
-
Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia
NCT00821600 ·Status: COMPLETED ·Phase: PHASE1
-
A 2-year Study of Patients With Schizophrenia Who Are Treated With Long-acting Injectable Risperidone.
NCT00261430 ·Status: COMPLETED ·Phase: PHASE4
-
Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA)
NCT00246194 ·Status: COMPLETED
-
An Observational Study to Assess Treatment & Outcomes Data in Patients Receiving Long-Acting Injectable Risperidone
NCT00774085 ·Status: COMPLETED